Loading...
XNAS
MDGL
Market cap12bUSD
Dec 05, Last price  
577.30USD
1D
-1.52%
1Q
33.36%
Jan 2017
3,774.50%
IPO
5,882.38%
Name

Madrigal Pharmaceuticals Inc

Chart & Performance

D1W1MN
XNAS:MDGL chart
P/E
—
P/S
71.08
EPS
—
Div Yield, %
—
Shrs. gr., 5y
6.68%
Rev. gr., 5y
%
Revenues
180m
00743,0002,615,000144,245,00014,803,0007,584,000147,00000000000000180,133,000
Net income
-466m
L+24.69%
-68,863,000-57,270,000-63,495,000-92,618,00079,088,000-37,467,000-47,380,000-62,790,000-90,192,000-86,161,000-68,671,000-26,388,000-31,154,000-32,811,000-72,812,000-197,444,000-241,078,000-299,314,000-373,630,000-465,892,000
CFO
-456m
L+40.51%
-61,882,000-52,985,00027,222,000-37,939,000-26,810,000-38,199,000-47,300,000-54,135,000-77,411,000-78,925,000-71,444,000-17,607,620-22,317,000-25,507,000-41,624,000-157,561,000-183,917,000-224,857,000-324,230,000-455,572,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.
URL
https://www.madrigalpharma.com/
IPO date
Feb 06, 2007
Employees
92
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT